Rhodes JM & Mato AR. (2021). Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Dove Medical Press.
Chicago Style (17th ed.) CitationRhodes JM and Mato AR. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Dove Medical Press, 2021.
MLA (9th ed.) CitationRhodes JM and Mato AR. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.